Home » Newsletters » BioWorld Science

BioWorld Science

March 9, 1998

View Archived Issues

Effects of EAA receptor antagonists on morphine tolerance and dependence

Company Profile: Andrx

KBR-7943, a novel Na+/Ca2+ exchange inhibitor

Benefits of finasteride in patients with benign prostatic hyperplasia

JTV-506, a potential antianginal agent

Beneficial effects of aspirin on endothelial dysfunction in patients with atherosclerosis

The role of ETA and ETB receptor subtypes in human blood vessels

DepoTech: Q4 and year-end 1997 highlights

Neurex: year-end 1997 highlights

Lilly antifolate evaluated in phase II

Favorable phase I results obtained with G-3139 in NHL

S-1 demonstrates excellent antitumor activity in phase II

Overview of preclinical and clinical evaluation of Russian nitrosourea

Viracept approved in Japan

Evidence of clinical efficacy of ukrain in colorectal cancer

Entropin goes public

Anticancer imidazoles from Merck & Co.

DepoCyt FDA review period extended in order to review additional patient data

Roche finalizes Corange acquisition

Once-a-day Cozaar introduced in Canada

Ritonavir in advanced HIV-1 disease

Antithromboxane therapy leads to clinical benefit in type II diabetics

New cisapride formulation introduced in U.K.

DepoMed, R.W. Johnson sign research agreement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...